LGVN Longeveron Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1721484 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-18.9%
TTM net income YoY-4.9%
TTM EPS YoY134.5%
Revenue 3-yr CAGR15.0%
Net income 3-yr CAGR—
Margins
Gross margin66.4%
Operating margin-2,020.8%
Net margin-1,921.7%
FCF margin-1,560.1%
EBITDA margin-1,952.1%
Returns
ROE-305.1%
ROA-162.4%
ROIC (approx.)—
Asset turnover0.08x
Leverage & solvency
Liabilities / assets60.8%
Debt / equity0.00x
Current ratio1.25x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.80x
Accruals ratio-31.8%
Payout ratio—
Capex / revenue14.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $115,000 | $287,000 | $398,000 | $365,000 | $137,000 | $316,000 | $381,000 | $603,000 |
| Cost of revenue | $44,000 | $105,000 | $134,000 | $108,000 | $12,000 | $170,000 | $106,000 | $73,000 |
| Gross profit | $71,000 | $182,000 | $264,000 | $257,000 | $125,000 | $146,000 | $275,000 | $530,000 |
| R&D expense | $3.96M | $3.19M | $2.32M | $2.72M | $3.85M | $2.95M | $2.52M | $1.99M |
| SG&A expense | $3.31M | $3.16M | $2.72M | $2.94M | $3.58M | $2.59M | $2.94M | $2.82M |
| Operating income | -$7.20M | -$6.17M | -$4.78M | -$5.40M | -$7.31M | -$5.40M | -$5.18M | -$4.28M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$6.13M | -$6.07M | -$4.74M | -$5.44M | -$7.22M | -$5.03M | -$5.01M | -$4.08M |
| EBITDA | -$7.00M | -$5.97M | -$4.58M | -$5.20M | -$7.11M | -$5.20M | -$4.98M | -$4.08M |
| EPS (basic) | -1.91 | -0.19 | -0.19 | — | -3.93 | -0.33 | -0.34 | — |
| EPS (diluted) | -1.91 | -0.19 | -0.19 | — | -3.93 | -0.33 | -0.34 | — |
| Weighted avg. shares (diluted) | 3.21M | 31.38M | 24.79B | — | 1.84M | 15.01M | 14.95B | — |
| Balance sheet | ||||||||
| Cash & equivalents | $7.25M | $10.08M | $15.76M | $4.66M | $9.24M | $10.33M | $14.33M | $19.23M |
| Short-term investments | — | — | — | — | — | — | $0 | $0 |
| Receivables | $64,000 | $65,000 | $68,000 | $104,000 | $52,000 | $31,000 | $29,000 | $84,000 |
| Current assets | $8.15M | $11.32M | $16.86M | $5.45M | $10.34M | $11.27M | $15.28M | $19.62M |
| PP&E, net | $1.45M | $1.60M | $1.65M | $1.84M | $2.12M | $2.26M | $2.29M | $2.45M |
| Intangibles | $2.17M | $2.20M | $2.24M | $2.29M | $2.31M | $2.32M | $2.29M | $2.40M |
| Total assets | $12.02M | $15.49M | $21.21M | $10.26M | $15.56M | $16.75M | $20.85M | $25.56M |
| Current liabilities | $6.53M | $4.31M | $4.34M | $4.09M | $4.94M | $3.28M | $2.72M | $2.58M |
| Total liabilities | $7.30M | $5.08M | $5.18M | $4.59M | $5.59M | $4.09M | $3.69M | $3.67M |
| Shareholders' equity | $4.71M | $10.40M | $16.03M | $5.67M | $9.97M | $12.66M | $17.16M | $21.89M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.69M | -$5.65M | -$4.37M | -$5.30M | -$5.05M | -$3.60M | -$4.70M | -$3.37M |
| Capital expenditure | $65,000 | $103,000 | $0 | $0 | $57,000 | $161,000 | $27,000 | $13,000 |
| Free cash flow | -$2.75M | -$5.76M | -$4.37M | -$5.30M | -$5.11M | -$3.76M | -$4.72M | -$3.39M |
| Investing cash flow | -$66,000 | -$103,000 | -$20,000 | -$64,000 | -$118,000 | -$263,000 | -$150,000 | -$123,000 |
| Financing cash flow | -$78,000 | $75,000 | $15.49M | $777,000 | $4.08M | -$133,000 | -$58,000 | -$50,000 |
| Depreciation & amortization | $200,000 | $200,000 | $200,000 | $200,000 | $200,000 | $200,000 | $200,000 | $200,000 |
| Stock-based compensation | $520,000 | $373,000 | $379,000 | $376,000 | $448,000 | $513,000 | $340,000 | $390,000 |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.